Fresenius Medical Care stock holds near EUR 39 as investors look to latest guidance

Published on 09/14/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock closed at EUR 39.45 on Xetra on September 11, 2026, remaining in a narrow range in early September. Recent price stability comes after the company’s latest guidance and interim figures earlier in 2026.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care stock (ISIN DE0005785802) closed at EUR 39.45 on Xetra on September 11, 2026, leaving the dialysis specialist trading in a tight corridor just below the 40-euro mark as investors digest its latest guidance and interim figures for 2026.

Stock trades in a narrow September range

On the Xetra trading day of September 11, 2026, Fresenius Medical Care AG shares ended the session at EUR 39.45, with intraday trading only reaching up to EUR 39.70 as reported by IT BOLTWISE on September 14, 2026.

According to the same overview from IT BOLTWISE, since the start of September 2026 the stock has moved in a corridor between roughly EUR 39.50 and EUR 39.70, with a closing price of EUR 39.45 also recorded on September 1, 2026, underscoring how constrained recent price action has been.

Market data underpin the calm share performance

Intraday price data compiled by Investing.com on September 14, 2026 show a derived Fresenius Medical Care quote at EUR 39.43, with an intraday high of EUR 39.52 and a low of EUR 38.78, corresponding to a gain of 2.58 percent on the day and trading volume of about 145,000 shares as of 07:04:47.

At this level, the share price remains close to the early-September corridor highlighted by IT BOLTWISE, suggesting that the modest intraday move on September 14, 2026 has not yet translated into a decisive breakout from the roughly EUR 39.50 to EUR 39.70 range.

Interim figures and guidance shape the 2026 narrative

For the fundamental backdrop, investors are still oriented toward Fresenius Medical Care AG’s latest interim results and guidance communicated earlier in 2026 on the investor-relations pages of Fresenius Medical Care, which outline revenue, earnings and margin trends for the most recent reporting period within the current fiscal year.

According to the financial calendar and report links on Fresenius Medical Care, the company continues to provide guidance for its full-year 2026 performance, including targets for revenue growth and profitability metrics that investors use to benchmark the current share price relative to expected operating progress.

Analyst consensus and earnings expectations

While specific analyst actions on Fresenius Medical Care AG are less prominently featured in this week’s search results, broader consensus data on the Fresenius group compiled by MarketScreener on September 14, 2026 indicate a Buy mean consensus with 14 analysts, an average target price of EUR 55.59 and spreads of more than 20 percent versus the last close of EUR 45.04 for Fresenius SE, highlighting a generally constructive view on the wider Fresenius universe.

Separate coverage of FMC Corporation on the New York Stock Exchange, which is a different entity from Fresenius Medical Care AG, shows that analysts tracked by MarketBeat assign an average Hold rating with an average price target of USD 14.38 and an Overweight rating with a USD 16.00 price objective from KeyCorp as of September 14, 2026, a reminder that investors must distinguish clearly between FMC Corporation and Fresenius Medical Care AG when interpreting ticker-based analyst data.

Stock price level and investor takeaway

As of the last completed Xetra trading day on September 11, 2026, Fresenius Medical Care stock traded at EUR 39.45, and intraday data for September 14, 2026 point to a level of around EUR 39.43 with a daily gain of about 2.6 percent and volume near 145,000 shares on Xetra per Investing.com data, leaving the shares close to their early-September trading corridor and giving investors a relatively stable entry point while they wait for the next set of detailed financial figures.